Creative Biogene is a leading biotechnology company which has the expertise in providing cardiac safety assay services for customers worldwide. Creative Biogene possesses sophisticated equipments, advanced technologies and highly experienced staffs, which are available to offer you the high-quality, comprehensive assay service with the most competitive price. Creative Biogene’s top priorities are to streamline the platform processes or work with you to design a process that meets your specific needs and expedites your process of drug discovery.
In the drug development process, drug-induced arrhythmia is a concern for pharmaceutical industry because it may manifest following the approval of new drugs and cause serious harm to patients. In order to reduce failure in later stages, in vitro pharmaceutical profiling which can provide crucial information to estimate drug candidates with potential toxicity early in drug discovery is needed. For the past decade, in vitro inhibition assays of hEGR were used to estimate the risk of delayed ventricular repolarization (QT prolongation)-related arrhythmia in humans. However, recent evidence has suggested that evaluation of hERG alone is not sufficient for cardiac safety assessment. Blockade or potentiation of other cardiac currents could also generate adverse effects in heart. Thus, to better predict proarrhythmic risks using in vitro assays, a comprehensive in vitro proarrhythmia assay (CiPA) has been proposed.
Comprehensive in vitro proarrhythmia assay (CiPA) comprises two distinct series of tests: (1) the in vitro study of drug effects on multiple ion channels (not just hERG) and incorporation of these effects in an in silico model of a human ventricular action potential (AP) in an effort to reconstruct the effects on ventricular repolarization and identify potential mechanism-based metrics that can assess proarrhythmia risk, and (2) confirmation of the ionic current and in silico results using human ventricular myocytes, likely derived from human-induced pluripotent stem cell (iPSC) cardiomyocytes. After years of development, Creative Biogene now has the expertise and ability in offering you unique preclinical services in the cardiac safety assays. Creative Biogene has confidence in providing you with the most affordable and comprehensive service to satisfy your different demands.
Creative Biogene is able to provide the following cardiac safety assay services to better predict the proarrhythmic liability of your test compounds:
Automated electrophysiology screening against multiple cardiac screen panels, including hERG, NaV1.5, CaV1.2, Kir2.1, KV1.5 etc.
Cardiac safety screen using iPSCs-derived cardiomyocytes.
Cardiac action potential assays of Purkinje fibers and papillary muscle.
Cardiac pharmacological study using acute isolated cardiomyocytes (from rabbit, Guinea pig or rats).
Advantages of cardiac safety assay services in Creative Biogene:
Knowledgeable in cardiac safety pharmacology and electrophysiology
Skilled bench scientists in patch clamp technology
Variety of assays to meet different demands
Reliable and shot turn-around time
With years of experience and expertise in this field, Creative Biogene can provide you the comprehensive services and highest quality results for cardiac safety assay of your test compounds. With the help of our talented scientists, Creative Biogene is confident in speeding your project progress and achieving ideal research goals with the most competitive price.
If you have any special requirements in cardiac safety assay services, please feel free to contact us at firstname.lastname@example.org or 1-631-626-9181. We are looking forward to working together with your attractive projects.
- Zou B. Ion channel profiling to advance drug discovery and development. Drug Discovery Today: Technologies, 2015, 18: 18-23.
- Fermini B, et al. A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. Journal of biomolecular screening, 2016, 21(1): 1-11.